THE European Commission has
approved expanded options for
pre-treatment prior to use of
Qutenza (8% capsaicin patch), the
first and only licensed high
concentration capsaicin cutaneous
patch for the treatment of peripheral
neuropathic pain in Europe.
The expansion means that before
application a patient may now take
an oral analgesic, or the treatment
area may be pre-treated with a
topical anaesthetic.The above article was sent to subscribers in Pharmacy Daily's issue from 15 Mar 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Mar 13
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.